<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>14 Urological cancers</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part19.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part21.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark19" class="s95" name="bookmark59">Chapter 14</a><a name="bookmark60">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_196.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark19">Urological cancers</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">ananya Choudhury and peter hoskin</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1 <span class="h4">Prostate cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Prostate cancer is the most common cancer in males and is the second leading cause of cancer deaths in the Western world. In 2015, there were over 47,000 new cases diagnosed, with over 11,000 deaths and a ten-year survival of 84%. For patients with organ-confined prostate cancer, management options include observation, active sur- veillance, radical prostatectomy, or radiotherapy (external beam or brachytherapy). For patients with locally advanced or metastatic disease treatment, options include a combination of hormone therapy, radiotherapy, or chemotherapy.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.2 <span class="s29">Diagnosis and staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.2.1 <span class="s98">Diagnosis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Prostate cancer is usually diagnosed by multiparametric magnetic resonance imaging (mpMRI) and trans-rectal ultrasound (TRUS) guided needle biopsy. As standard, 12 cores are taken, although the diagnostic yield increases when more cores are taken. If more biopsies are required for diagnostic purposes or for more targeted approaches, transperineal template biopsies are acquired, also using TRUS guidance. Although prostate cancer classically appears hypoechoic in comparison to the surrounding per- ipheral zone, its ultrasonic appearance is variable. For this reason, TRUS is not used to detect or direct biopsies to malignant lesions but to target the gland for systematic sampling. Recent studies have confirmed the superiority of MRI for prostate cancer, with mpMRI now the standard of care for diagnosis and targeting of biopsies.<span class="s22">1 </span>The PI-RADS (Prostate Imaging Reporting and Data System) reporting scheme is used to standardize evaluation of prostate MRI as shown in Table 14.1. The score is made up of parameters from T2-weighted, diffusion-weighted (DWI), and dynamic-contrast en- hanced MRI (DCE-MRI). The scale is based a score of 1–5 for T2-weighted and DWI, and on a score of yes or no for DCE-MRI. A composite likelihood score is given for each lesion, with 1 being most likely benign and 5 being highly likely to be a clinically significant cancer.</p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.2.2 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Prostate cancer may be staged clinically with digital rectal examination (DRE), but more accurate estimates of tumour burden will be obtained using imaging. The</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 14.1 <span class="s52">pi-RaDs (prostate imaging reporting and data system) score</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_197.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_198.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_199.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 161%;text-align: left;">pi-RaDs 1   Very low (clinically significant cancer is highly unlikely to be present) pi-RaDs 2   low (clinically significant cancer is unlikely to be present)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_200.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_201.png"/></span></p><p class="s54" style="padding-left: 5pt;text-indent: 0pt;line-height: 161%;text-align: left;">pi-RaDs 3   intermediate (the presence of clinically significant cancer is equivocal) pi-RaDs 4   high (clinically significant cancer is likely to be present)</p><p class="s54" style="padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">pi-RaDs 5   Very high (clinically significant cancer is highly likely to be present)</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_202.png"/></span></p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 109%;text-align: left;">Reproduced with permission from american College of Radiology, ‘prostate imaging—Reporting and Data system (pi-RaDs) 2019, Version 2.1’. Copyright © american College of Radiology.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">tumour, node, metastasis (TNM) staging classification is shown in Table 14.2. TRUS is not used for staging as its accuracy is no better than DRE and there is significant inter-operator variability. Computed tomography (CT) does not allow reliable tumour visualization but gross disease extension or enlarged adenopathy may be seen.</p><p class="s91" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">T stage <span class="p">mpMRI is the imaging modality of choice for local staging, including T1- weighted, T2-weighted, DCE and DWI sequences. Intraprostatic lesions and zonal anatomy are best demonstrated on T2-weighted images (Figure 14.1). Approximately 70% of prostate cancers arise in the PZ, 30% in the central gland.</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Prostate cancers are typically of low-signal intensity within the PZ on T2-weighted images (Figure 14.1). However, low-signal intensity lesions in the PZ can also be caused by prostatitis, scarring, and post-biopsy haemorrhage. MRI is performed ideally be- fore biopsy. The PROMIS study<span class="s22">1 </span>has shown that pre-biopsy multi-parametric MRI can reduce the over-diagnosis of clinically insignificant prostate cancer while improving that of clinically significant cancer.</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 94%;text-align: justify;">If biopsy has taken place, it is recommended to delay the MRI for a minimum of 3-4 weeks after biopsy<span class="s22">2 </span>to allow post-biopsy trauma to settle. In terms of staging accuracy, the reported sensitivity and specificity of MRI in detecting extracapsular spread is highly variable.<span class="s22">3,4 </span>The sensitivity and specificity of MRI in detecting sem- inal vesicle invasion (Figure 14.2) is also variable, ranging from 85–97% and 21–63% respectively.<span class="s22">5</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Functional MRI sequences, such as DCE-MRI, DWI, and MR spectroscopy (MRS) have been described in the assessment of prostate cancer. DWI and DCE-MRI have become part of routine staging in recent years. DWI measures Brownian motion of water, reflecting the cellularity of tissue. Diffusion of water is reduced in prostate cancer compared to normal tissue and is measured using the apparent diffusion co- efficient (ADC). The values can be mapped by voxel, with an area of malignant tissue showing a 20–40% lower ADC measurement compared to normal tissue reflecting higher cell density.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">DCE-MRI provides a means of assessing tissue perfusion and permeability by imaging the passage of intravenous gadolinium through the tissues. In prostate cancer, MR spectra from protons in choline and citrate can be assessed. High levels of cit- rate and intermediate levels of choline are observed within the normal PZ. However, prostate cancer cells have a reduced capacity for citrate production and increased</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 14.2 <span class="s52">tnM classification for prostate cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T primary tumour</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">tX</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">primary tumour cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t0</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">no evidence of primary tumour</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Clinically inapparent tumour that is not palpable</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1a</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour incidental histological finding in 5% or less of tissue resected</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1b</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour incidental histological finding in more than 5% of tissue resected</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t1c</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour identified by needle biopsy (e.g. because of elevated psa)</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour that is palpable and confined within prostate</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2a</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour involves one half of one lobe or less</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2b</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour involves more than half of one lobe, but not both lobes</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t2c</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour involves both lobes</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour extends through the prostatic capsule*</p></td></tr><tr style="height:26pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3a</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;line-height: 111%;text-align: left;">extraprostatic extension (unilateral or bilateral) including microscopic bladder neck involvement</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t3b</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">tumour invades seminal vesicle(s)</p></td></tr><tr style="height:26pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">t4</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic wall</p></td></tr><tr style="height:35pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">note</p><p class="s106" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 109%;text-align: left;">*invasion into the prostate apex or into (but not beyond) the prostatic capsule is not classified as t3, but as t2.</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">N regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">nX</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Regional lymph nodes cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n0</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">no regional lymph node metastasis</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Regional lymph node metastasis</p></td></tr><tr style="height:26pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">note</p><p class="s106" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">Metastasis no larger than 0.2 cm can be designated pnmi.</p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">no distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1a</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">non-regional lymph node(s)</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1b</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Bone(s)</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1c</p></td><td style="width:296pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">other site(s)</p></td></tr><tr style="height:32pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">note</p><p class="s106" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">When more than one site of metastasis is present, the most advanced category is used. (p)M1c is the most advanced category.</p></td></tr></table><p class="s14" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 107%;text-align: left;">Reproduced with permission from sobin lh, Gospodarowicz MK, Wittekind Ch. <span class="s83">UICC TNM Classification of Malignant Tumours</span>. 8th ed. © 2017 Wiley Blackwell.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 74pt;text-indent: 0pt;text-align: left;"><span><img width="247" height="192" alt="image" src="Image_203.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: justify;">Fig. 14.1 <span class="s52">prostate cancer. axial t2-weighted images through the prostate showing the zonal anatomy: central gland (CG) and peripheral zone (pZ). prostate cancer is seen as the low signal area (arrow) in the right pZ.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">cell turnover results in higher choline levels. Although MRS was initially reported as promising an increase in diagnostic yield, it is rarely used in routine practice.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Most prostate imaging is undertaken using a 1.5 T magnet; however, 3 T imaging provides an opportunity for better spatial, contrast, or temporal resolution with smaller voxel sizes.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There will be a small group of patients for whom MR is contraindicated, usually because of implanted devices such as a pacemaker. In these patients, computed tom- ography (CT) will usually be undertaken, but will show only gross changes in gland pathology although it remains a useful tool for lymph node staging (see below).</p><p class="s91" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">N stage <span class="p">CT and MRI are the principal imaging modalities used in the detection of lymph node spread (Figure 14.2). The routine use of mpMRI means that as well as staging the primary tumour, the regional lymph nodes will be assessed. The detection of lymph node metastases by CT or MR is based on size (Table 14.2). Hyperplastic or</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="143" alt="image" src="Image_204.png"/></span></p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(a)</p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(a)</p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(b)</p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(b)</p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(c)</p><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s79" style="text-indent: 0pt;line-height: 7pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: justify;">Fig. 14.2 <span class="s52">t2-weighted MR images (a) and (b) axially through the prostate, and (c) coronally through the seminal vesicles shows prostate cancer with extraprostatic spread (arrowhead), seminal vesicle invasion (dashed arrow) (stage t3b), and nodal disease (arrow).</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">reactive nodes with no tumour involvement will give rise to false positive results. The sensitivity and specificity of CT in the detection of node metastases has a range of 25– 78% and 77–98% respectively.<span class="s22">6 </span>The sensitivity and specificity of MRI in the detection of lymph node metastases has a range of 30–100% and 94–100% respectively.<span class="s22">7,8</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Lymph node-specific contrast agents, ultra-small particles of iron oxide (USPIO), have been evaluated in the detection of node involvement with malignancy. The USPIO are taken up by macrophages in the reticuloendothelial system, causing loss of signal on T2- and T2*-weighted sequences in normal nodes. A portion of the nodes infiltrated with metastatic disease do not take up the USPIO and hence remain of high signal intensity. A systematic review has shown that sensitivity and specificity of USPIO with MRI is higher than that of MRI alone.<span class="s22">9 </span>However, the limited availability of USPIO has meant that its application has been mainly in the Netherlands where it is licensed for production.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">While positron emission tomography/CT (PET/CT) has limited value currently in local tumour staging (due to uptake in benign prostatic hyperplasia and prostatitis), it has a role in nodal staging in high-risk prostate cancer. To date, the most commonly used PET tracer has been choline (11-C or 18F-choline) with pooled sensitivity and specificity of 60% and over 90%, respectively, with uptake in both enlarged and normal sized involved lymph nodes. More recently, new tracers have been introduced. 18F- fluciclovine, a synthetic amino acid analogue, has been licensed for suspected prostate cancer recurrence with sensitivity and specificity &gt;85%; increased fluciclovine uptake into prostate cancer cells is due to upregulated amino acid transporters, including ASCT2 and LAT1. Also, 68-Ga and 18F-labelled tracers targeting prostate-specific membrane antigen (PSMA) are promising, with superiority compared to CT<span class="s22">10 </span>as over 90% of prostate cancers overexpress PSMA, a transmembrane glycoprotein. Sensitivity has been shown to be 60–70% with specificity of over 95%. At present there is limited data on its routine use and no evidence that PSMA PET/CT at staging impacts on survival. Nevertheless, it is expected that PSMA PET will replace other tracers as the first choice in the future (Figure 14.3).</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;"><span class="s91">M stage </span>Distant metastasis in prostate cancer is most commonly to the bone, with the axial skeleton involved in 85% of patients dying from prostate cancer. Bone scin- tigraphy with technetium 99m diphosphonate is the main imaging modality used in staging to screen for metastatic bone disease (Figure 14.4).<span class="s22">11 </span>Bone metastases dem- onstrate increased uptake of tracer; however, plain film correlation may be needed to exclude other causes of increased tracer uptake, such as degenerative disease or Paget’s disease since the technetium uptake in fact represents osteoblastic activity. The use of whole body MRI (Figure 14.5) has been increasing, with recent international guidelines published recommending its use for patients where there is some uncer- tainty regarding the presence of bone metastases as its sensitivity is higher than either choline PET/CT or bone scintigraphy. However, whole body MRI may be less sensitive than either 68Ga-PSMA-PET/CT or NaF-PET/CT. Other sites of metastatic disease are extremely rare and occur late.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 110pt;text-indent: 0pt;text-align: left;"><span><img width="149" height="259" alt="image" src="Image_205.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.3 <span class="s52">Coronal psMa pet/Ct image in a patient with biochemical relapse after radical prostatectomy shows recurrence with increased uptake in right common iliac and hilar nodes.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="168" height="244" alt="image" src="Image_206.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.4 <span class="s52">Metastatic prostate cancer. Whole body bone scintigraphy (a) showing multiple bone metastases. (b) Following treatment with hormone therapy there has been resolution of the metastatic disease.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="319" alt="image" src="Image_207.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.5 <span class="s52">Whole body MRi with inverted grey-scale high-b-value DWi image (a), corresponding t2-weighted (b) and high b-value DWi (c) image showing left mesorectal and internal iliac nodal disease (white arrow) from prostate cancer.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.3 <span class="s29">Imaging for radiotherapy planning</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.1.3.1 <span class="s98">External beam radiotherapy</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Cross-sectional imaging plays a central role in the definition of target volumes, treat- ment planning, and verification of treatment.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Modern external beam radiotherapy (EBRT) relies on CT for treatment planning. However, it is clear that MRI can offer advantages for radiotherapy treatment plan- ning (RTP). In prostate planning studies of co-registered CT-MRI, investigators have reported better definition of prostate boundaries and substantially smaller treatment volumes by up to 40%.<span class="s22">12 </span>MRI can substantially reduce uncertainty in target volume definition compared to CT, especially at the prostatic base and apex. The smaller but more appropriate treatment volumes may also enhance the therapeutic ratio when dose escalation schemes are employed.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In order to use MRI information for RTP, several important issues need to be ad- dressed. These include defining and correcting for MR image distortions, overcoming the lack of electron density information in MR images which are needed for dose computation, as well as other potential limitations such as patient claustrophobia, and other contraindications (e.g. <i>in situ </i>pacemakers). Sources of MR image distor- tion include system-related and object-induced (i.e. patient dependent) effects. These</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="389" height="179" alt="image" src="Image_208.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.6 <span class="s52">t2-weighted (a) and corresponding DWi aDC parametric (b) images showing a restricted, left peripheral zone, dominant intraprostatic lesion.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">effects are important as accurate geometric imaging data is needed for RTP and they can now be assessed, quantified, and minimized through the use of correction algo- rithms. After distortion correction, MR images can either be assigned bulk attenuation factors for the relevant volumes of interest or co-registered and fused with CT im- ages so that the superior tissue definition from MRI can be transferred to the CT data for treatment planning and subsequent treatment verification procedures. The main challenge is that of accurate co-registration given the difference in the two imaging modalities. With the introduction of MR simulation, synthetic CT has been devel- oped to aid MR-only planning. With mpMRI, significant tumour within the gland, the dominant intraprostatic lesion (DIL) (Figure 14.6), can be identified which has led to studies where the DIL can be boosted to a higher dose than that of the rest of the prostate gland.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.1.3.2 <span class="s98">Brachytherapy</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Brachytherapy is used in the treatment of prostate cancer both as a primary treatment and as a boost with external beam. Modern image guided brachytherapy is under- taken using a transperineal approach with real time transrectal imaging to accurately place radiation sources, typically I125 seeds, or afterloading catheters for High Dose Rate (HDR) brachytherapy. An example of a TRUS guided LDR seed implant is shown in Figure 14.7. HDR brachytherapy also uses TRUS to define the positioning of the afterloading applicators and guide implantation (Figure 14.8). The CTV is then de- fined using either TRUS, CT, or MRI (Figure 14.9<b>)</b>. Non-rigid deformation registra- tion programmes are now available which enable fusion of diagnostic MR with TRUS to improve CTV definition.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.1.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The mainstay of response assessment following treatment for prostate cancer is serial PSA monitoring. Further evaluation, including imaging, is triggered by a rising PSA after treatment or in the case of post-prostatectomy a detectable PSA &gt;0.2 ng/ml. In</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="166" alt="image" src="Image_209.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 14.7 <span class="s52">transrectal ultrasound images of lDR i125 implant showing (a) transverse and</span></p><p class="s52" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">(b) sagittal ultrasound views with radiation distributions shown by coloured isodose lines.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">patients who have had previous prostatectomy, MRI is used to detect local tumour re- currence. Recurrent disease is seen as asymmetrical soft tissue in the prostate bed or pelvis. TRUS in this setting may be used to obtain a biopsy and get pathological con- firmation of recurrence.<span class="s22">13 </span>Regional lymph node recurrence may also be seen.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">After EBRT, detection of recurrent disease is made more difficult by post- radiotherapy change within the gland. Imaging is performed to assess the primary site, lymph nodes, and the skeleton. With the emergence of re-irradiation of the pros- tate and the treatment of oligometastatic disease, there is a move to image patients earlier on relapse with lower PSAs. mpMRI may demonstrate recurrent sites within the prostate as may choline or PSMA PET/CT to target with focal ablative techniques.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="371" height="252" alt="image" src="Image_210.jpg"/></span></p><p class="s70" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: right;">urethra</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.8 <span class="s52">tRus image of implanted hDR catheters in preparation for hDR after loading brachytherapy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="280" alt="image" src="Image_211.gif"/></span></p><p class="s70" style="padding-top: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">urethra</p><p class="s70" style="padding-top: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">urethra</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="padding-top: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">urethra</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.9 <span class="s52">axial MRi image of implanted hDR catheters in preparation for hDR after loading brachytherapy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Where such treatment is considered and where oligometastases are being considered for surgery or non-surgical ablation then further investigation to exclude other sites of disease is imperative.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT for lymph node status and bone scintigraphy for skeletal imaging is most com- monly repeated after treatment (Figure 14.4) where there is a rising PSA. The utility of bone scintigraphy in asymptomatic patients with biochemical disease relapse depends on PSA level. It is of no added diagnostic value unless the PSA serum levels are &gt;20 ng/mL or unless the PSA velocity is &gt;20 ng/mL/year. Whole body MRI has greater sensitivity for de- tection of bone metastases and where available is preferred. Patients with localized bone pain may be further investigated with plain X-ray or MRI of the relevant site.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">PET/CT is recommended for suspected recurrence patients with rapidly rising PSA and negative or equivocal conventional imaging. Choline PET/CT may yield true posi- tive findings in recurrent prostate cancer with serum PSA levels &lt;5 ng/mL. PSMA PET/CT scans have been shown to detect recurrence in ~50% of men where the PSA level is &lt;1.0 ng/ml, ~70% of patients where the PSA level is 1.0–2.0 ng/ml, and ~90% of patients where the PSA level is &gt;2.0 ng/ml.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.1.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">The most important prognostic factors in prostate cancer are PSA level, tumour stage, and Gleason score.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">TRUS is used to direct systematic sampling of the prostate at present, but the use of MR-targeted biopsies is increasing.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">MRI is the imaging modality of choice for staging of the primary tumour.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">CT and MRI have a similar sensitivity and specificity for the detection of lymph node metastases. New PET/CT tracers (fluciclovine or PSMA) may aid this diagnosis.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">CT is the current standard for radiotherapy planning, but MRI-assisted planning can add complementary information.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">TRUS provides real time imaging for implantation and volume definition for brachytherapy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2 <span class="h4">Bladder cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Bladder cancer is the most common tumour of the urinary tract and comprises 6–8% of all male malignancies and 2–3% of all female malignancies.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2.2 <span class="s29">Diagnosis and staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2.2.1 <span class="s98">Diagnosis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Diagnosis of bladder cancer is made at cystoscopy and biopsy. Imaging is used to as- sess upper urinary tracts with CT urography (CTU) used as standard. CTU images are obtained of the bladder and renal tract when contrast media has reached the renal collecting system and bladder. CTU protocols usually incorporate pre-contrast as well as images in the nephrographic phase of enhancement, that is, parenchymal enhance- ment of the kidney. These techniques therefore allow for detailed views of the renal parenchyma and the collecting systems. Mass lesions of the bladder and renal tract as well as pelvi-calyceal abnormality can all be evaluated simultaneously.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2.2.2 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;"><span class="s91">T stage </span>Primary tumour staging with cystoscopy and transurethral resection (TUR) is accurate in the evaluation of superficial tumours.<span class="s22">14 </span>For muscle-invasive tumours, how- ever, clinical staging can understage by as much as 50%. In these cases, imaging will give added information to help assess the extent of tumour spread. US (Figure 14.10) may be useful in demonstrating a bladder tumour but is not routinely used in primary tumour staging, as the assessment of peri-vesical tumour spread is limited and it does not allow assessment of local lymph nodes.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is the imaging modality of choice for local staging of bladder cancer. It is in- accurate in the evaluation of stage T1 and T2a tumours. However, there is some evidence to suggest that MRI can distinguish between T2a and T2b tumours. Invasion of the deep muscle layer by T2b tumours on T2-weighted imaging is demonstrated by disruption of the normal low-signal intensity bladder wall (Figure 14.11). Both T1- and T2-weighted sequences demonstrate T3b disease due to the contrast between tumour and perivesical fat. The staging error is similar for CT in the region of 30%. MRI is superior to CT in the assessment of local organ invasion due to superior contrast resolution and multiplanar imaging capability. Gadolinium-enhanced dynamic scanning techniques may improve visualization of depth of bladder wall and organ invasion (Table 14.3).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="300" height="237" alt="image" src="Image_212.gif"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.10 <span class="s52">transitional cell carcinoma of the bladder. longitudinal us image showing large mass (arrow) at the dome of the bladder.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="404" height="146" alt="image" src="Image_213.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 14.11 <span class="s52">transitional cell carcinoma of the bladder. axial (a) t1-weighted and (b) t2- weighted MR images showing a large intraluminal tumour (arrow) involving the left lateral bladder wall. the role of mp-MRi is yet to be determined in bladder cancer, but there has been an attempt to standardize the reporting in a way analogous to prostate, called the ViRaDs system, using a composite of t2, DCe, and DW-MRi.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 14.3 <span class="s52">ViRaDs imaging reporting system for bladder cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:15pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Vi-RaDs 1</p></td><td style="width:267pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">Muscle invasion is highly unlikely</p></td></tr><tr style="height:15pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Vi-RaDs 2</p></td><td style="width:267pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">Muscle invasion is unlikely to be present</p></td></tr><tr style="height:15pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Vi-RaDs 3</p></td><td style="width:267pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">presence of muscle invasion is equivocal</p></td></tr><tr style="height:15pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Vi-RaDs 4</p></td><td style="width:267pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">Muscle invasion is likely</p></td></tr><tr style="height:15pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Vi-RaDs 5</p></td><td style="width:267pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">invasion of muscle and beyond the bladder is very likely</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 108%;text-align: left;">adapted with permission from panebianco V et al. ‘Multiparametric magnetic resonance imaging for bladder cancer: development of Vi-RaDs (Vesical imaging-Reporting and Data system)’. <span class="s83">European urology</span>. Vol. 74, issue 3, pp.294–306. Copyright © 2018 elsevier ltd.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="300" height="168" alt="image" src="Image_214.gif"/></span></p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.12 <span class="s52">transitional cell carcinoma of the bladder. Ct showing an enhancing soft tissue mass (arrow) arising from the anterior bladder wall with stranding in the peri-vesical fat suspicious of extra-vesical spread.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In patients who are unable to undergo MR imaging, CT imaging of the abdomen and pelvis is performed with a full bladder and intravenous contrast. Delayed images with contrast in the ureters and bladder are useful in defining the extent of tumour at the bladder base and dome and spread into the ureters. CT cannot differentiate be- tween the bladder wall layers and therefore cannot differentiate between stage T1, T2a, and T2b tumours. In addition, residual bladder wall thickening following TURBT for T1 and T2a tumours is indistinguishable from muscle-invasive disease on CT. The main role of CT is to distinguish bladder tumours confined to the bladder wall from those that extend into the perivesical fat (Figure 14.12). However, the correlation be- tween CT findings and tumour extent in cystectomy specimens is only 65–80%. Pelvic sidewall and local organ invasion is demonstrated by soft tissue extension from the main tumour.</p><p class="s91" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">N stage <span class="p">Lymphatic spread of bladder cancer occurs to the perivesical, presacral, hypo- gastric, obturator, and external iliac nodes, followed by common iliac and para-aortic nodes. Both CT and MR rely on nodal size to define abnormality and will therefore not detect early tumour infiltration without nodal enlargement. The use of FDG PET/CT in local staging is limited by urinary excretion of the tracer; however, it may be useful for staging of lymph node and distant metastases, with guidelines recommending its use prior to any extensive surgery.</span><span class="s22">15</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;"><span class="s91">M stage </span>Distant metastases occur in advanced disease to bone, lungs, brain, and liver. Chest, abdomen, and pelvis CT with contrast is routinely performed in all patients to assess distant sites. FDG PET/CT may have a role also but bone scintigraphy is not routinely indicated in asymptomatic patients,<span class="s22">16 </span>but should be considered in high-risk patients and those with symptoms suggestive of bone involvement with suspicious findings confirmed on plain radiographs or MRI.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.2.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT is the standard imaging method used for RTP whereby three-dimensional con- struction permits proper identification of the whole bladder in relation to the</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">surrounding critical organs and normal tissue such as the bowel and rectum. Extra tumour localization information is also obtained from clinical maps of the bladder during cystoscopy and MRI. The main issue for bladder radiotherapy is that there is substantial variation on a day-to-day basis of bladder position and size due to bladder filling and emptying. This requires a larger planning margin of up to 1.5–2 cm to avoid a geographical miss. A variety of image guided radiotherapy (IGRT) methods are being evaluated to compensate for this bladder variation and can reduce the size of the planning margin needed. These methods use serial CT/MRI scans to assess a composite bladder volume (adaptive IGRT) or cine MR with cone beam CT to predict the daily volume bladder volumes (predictive IGRT). Fiducial markers have also been implanted into the bladder wall as another means of providing image guidance or to enable boosting of the bladder. Lipiodol is a radio-opaque contrast agent that can be injected into the bladder tumour bed at TURBT.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">14.2.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">After treatment of muscle-invasive bladder carcinoma with radical EBRT, follow-up serial cystoscopy and imaging is recommended. As recurrent disease may be local or metastatic, imaging of both the pelvis and abdomen is recommended Although retro- peritoneal recurrence usually occurs in association with pelvic node metastases, it may be an isolated finding in 10% of patients. Furthermore, these patients remain at risk of further metachronous tumours in the remaining urinary tract, which should be peri- odically evaluated using a CTU.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT performed following EBRT has been shown to be relatively inaccurate in local tumour assessment due to the difficulty in distinguishing tumour from bladder wall thickening due to radiation fibrosis. MRI of the bladder performed following EBRT demonstrates abnormal signal intensity of the outer muscle layer on T2- weighted sequences and enhancement on contrast-enhanced T1-weighted images. Contrast enhancement cannot reliably distinguish between tumour recurrence and post-radiotherapy change. Residual or recurrent tumour has an earlier onset of en- hancement than fibrotic tissue, which may be detected by DCE MRI in follow-up post-EBRT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">14.2.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 7pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Clinical staging is accurate in early stage disease, but inaccurate for evaluating in- vasive tumours spreading beyond the bladder.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">MR is superior to CT for staging early tumours.</span></p><p class="s23" style="padding-top: 3pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">CT is unreliable for staging tumours confined to the bladder wall, but accurate for staging advanced disease.</span></p><p class="s23" style="padding-top: 3pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Radiotherapy uses CT for treatment planning. New adaptive strategies with IGRT are needed to deal with the substantial variation in bladder size and position from day to day.</span></p><p class="s23" style="padding-top: 3pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Serial cystoscopy with CT are used for monitoring response and detecting recur- rent disease.</span></p><p class="s96" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3 <span class="h4">Upper urinary tract urothelial tumours</span></p><p class="s97" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3.1 <span class="s29">Clinical background</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Tumours of the upper urinary tract urothelium are much less common than either bladder or renal cell carcinomas. Ureteric transitional cell carcinomas (TCCs) are less common still, arising most commonly in the distal ureter. Upper urinary tract TCCs are commonly multifocal. Multifocal, ipsilateral TCCs develop in 14–30% of patients.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The diagnostic evaluation of the upper tract urothelial cancer forms part of the as- sessment of haematuria as described for bladder tumours in section 14.2. Staging is performed with contrast enhanced CT. Though MRI is comparable to CT, it is not used in routine staging of TCC of the renal collecting system but is useful in assessing vascular invasion by infiltrating tumours. The multi-focal nature of the disease means the whole urinary tract needs to be studied. The accuracy of CT for staging upper tract TCC has been shown to be 50% or less and it is unable to differentiate T1 and T2 tumours. The lymphatic spread depends on the site of the primary lesion, which, due to the periureteric lymphatics, can be to nodes in the retroperitoneum or pelvis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy has only a palliative role in controlling pain and haemorrhage associated with advanced disease using simple CT-based techniques.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Post-surgery, follow-up CT of the abdomen and pelvis is performed to assess for evidence of tumour recurrence. The contralateral collecting system is studied radio- graphically with CTU.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.3.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Urothelial tumours are often multi-focal and hence require imaging and evaluation of the whole renal tract using CTU.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Staging is performed with CT but this is relatively inaccurate.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">14.4 <span class="h4">Testicular cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.4.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Testicular cancers comprise 1–1.5% of all male neoplasms but are the most common neoplasm in young men. They are important because &gt;95% are curable. Germ cell tumours (GCT) comprise 95% of testicular neoplasms and are subdivided into seminomas (40%) and non-seminomatous germ cell tumours (NSGCT) (60%).</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patients with testicular tumours typically present with a painless scrotal mass, al- though occasionally they may present with features of metastatic disease.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.2 <span class="s29">Diagnosis and staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.2.1 <span class="s98">Diagnosis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Diagnosis of testicular GCT is at biopsy or orchidectomy. Scrotal US is used to confirm diagnosis and look for other abnormalities such as microlithiasis in the contralateral testis. Scrotal US has a sensitivity of almost 100% for the detection of testicular tu- mours (Figure 14.13).<span class="s22">17</span></p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.2.2 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Staging is based on the TNM classification<span class="s22">18 </span>and patients are categorized into good, intermediate, and poor prognostic groups using the international germ cell cancer collaborative group (IGCCCG) classification (Table 14.4). Initial staging is with a contrast-enhanced CT of the thorax, abdomen, and pelvis.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Testicular GCT spreads via the lymphatics to the retroperitoneal nodes in a pre- dictable pattern. Right-sided tumours initially spread to the aorto-caval nodes and nodes around the inferior vena cava. Left-sided tumours initially spread to the left para-aortic and pre-aortic nodes (Figure 14.14). Spread to the iliac and inguinal nodes usually occurs only in association with large volume retroperitoneal disease or with a history of testicular maldescent or surgery interfering with the lymphatic drainage, for example pelvic surgery.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Haematogenous spread occurs most commonly to the lungs; other sites include brain, bone, and liver. CT of the brain is indicated in those patients where there is clinical suspicion or with high-risk factors such as multiple lung metastases or HCG</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">&gt;10000 mIU/ml as brain metastases may be asymptomatic.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is not used routinely in staging but has a role in the investigation of suspected brain metastases, meningeal disease, and spinal cord involvement, and in problem</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 74pt;text-indent: 0pt;text-align: left;"><span><img width="247" height="201" alt="image" src="Image_215.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.13 <span class="s52">testicular cancer. us showing ill-defined hypoechoic intratesticular tumour (arrows).</span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Table 14.4 <span class="s52">international Germ Cell tumour Consensus Conference (iGCCCG) classification</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:14pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">NSGCT</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Seminoma</p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Good prognosis—all of the following:</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Good prognosis:</p></td></tr><tr style="height:26pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 16pt;text-indent: -8pt;line-height: 106%;text-align: left;">◆ <span class="s99">aFp &lt;1000ng/ml and hCG &lt;5000iu/l (1000 ng/ml) and lDh &lt;1.5 × n </span><span class="s85">and</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">no npVM</span></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">non-mediastinal primary</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">any primary site</span></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">no npVM</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">normal aFp, any hCG, any lDh</span></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">intermediate prognosis—all of the following:</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">intermediate prognosis:</p></td></tr><tr style="height:26pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 16pt;text-indent: -8pt;line-height: 106%;text-align: left;">◆ <span class="s99">aFp 1000–10,000 ng/ml, or hCG 5000–50,000 iu/l, or lDh 1.5–10 × n </span><span class="s85">and</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">npVM present</span></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">non-mediastinal primary site </span><span class="s85">and</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">no npVM</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">poor prognosis—any of the following:</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">aFp &gt;10,000 ng/ml or hCG &gt;50,000 iu/l or lDh</span></p><p class="s99" style="padding-left: 16pt;text-indent: 0pt;text-align: left;">&gt;10 × n <span class="s85">or</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">Mediastinal primary site </span><span class="s85">or</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:198pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">npVM</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: left;">aFp, alpha feto-protein; hCG, human gonadotrophin; lDh, lactate dehydrogenase; n, upper limit of normal; npVM, non-pulmonary visceral metastases.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="303" height="224" alt="image" src="Image_216.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.14 <span class="s52">testicular germ cell carcinoma. Ct shows enlarged left para-aortic lymph nodes (arrow) in a patient with non-seminomatous germ cell tumour.</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">solving if CT images are indeterminate. FDG PET/CT does not improve staging in pa- tients with clinical stage I disease and is not recommended for primary staging.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Adjuvant radiotherapy has been replaced by high-dose carboplatin in most patients with stage I seminoma where there is a high risk of recurrence. Radiotherapy is used in exceptional cases where carboplatin is contraindicated, such as patients with im- paired bone marrow function or severe cardiovascular morbidity. Radiotherapy has been the standard treatment of patients with stage IIA and IIB seminoma. An alter- native to radiotherapy is cisplatin-based combination chemotherapy. Planning uses contrast-enhanced CT with the nodal CTV based on vascular anatomy. The renal outlines are used to identify the renal hilar lymph nodes as well as limit the dose to the kidneys.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Men with low-risk testicular cancer after orchidectomy are offered surveillance. CT of the chest and abdomen is recommended unless the risk of pelvic relapse is high. The frequency of CT scans has been reduced to 3 and 12 monthly in the first year, and preliminary results from the Medical Research Council TRISST study suggest that reduced surveillance is non-inferior to standard surveillance and that MR is non-inferior to CT. CT is the main imaging modality used in routine follow-up of metastatic disease. Change in size or appearance of metastases and residual masses on CT are the main criteria used to assess response to therapy, alongside serum marker changes where detectable (Figure 14.15). Cystic and fatty change, which is readily as- sessed using CT, is associated with mature differentiated teratoma and may indicate the need for surgical removal.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Seminoma is extremely sensitive to chemo- and radiotherapy, such that a residual mass post-treatment usually represents fibrosis or necrosis. The CT findings may be allied to reduction in serum marker levels. In seminoma, FDG PET/CT may have a role in the assessment of residual masses after chemotherapy. A negative FDG PET/CT is 100% sensitive for absence of residual disease.<span class="s22">16</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In NSGCT, FDG PET/CT is less useful for evaluation of patients with residual masses as differentiated teratoma has variable low or no uptake and cannot be distin- guished from fibrosis or necrosis.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Detection of recurrent disease relies on careful follow-up with a combination of clinical assessment, serum markers, chest radiographs, and abdominal CT.</p><p class="s97" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.4.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">CT is the imaging modality of choice for staging testicular tumours.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Regular CT monitoring is essential in the follow-up of testicular GCTs.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">FDG PET may have a role in the evaluation of a residual mass following treatment.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="389" height="157" alt="image" src="Image_217.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.15 <span class="s52">testicular germ cell carcinoma. Ct (a) showing extensive paraaortic nodal disease (arrow) in a patient with metastatic seminoma. Ct following chemotherapy</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">(b) shows a significant reduction in the volume of nodal disease (arrow).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5 <span class="h4">Penile cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Penile cancer is an uncommon malignancy with an incidence of 1.3 per 100,000 men in the UK in 2003.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5.2 <span class="s29">Diagnosis and staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5.2.1 <span class="s98">Diagnosis</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Diagnosis of the primary lesion is with a biopsy and imaging is not needed because the tumour is visible on examination.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5.2.2 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Local staging is with US or MRI. Both can assist in identifying the depth of tumour invasion, particularly with regard to corpora cavernosa infiltration. US is often used as the initial imaging modality, with MRI as an alternative if US is inconclusive. MRI is more accurate at demonstrating corporal invasion or urogenital diaphragm involve- ment than US, and can help determine the extent of tumour along the surface of the penis, when the tumour is &gt;2 cm.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Lymphatic spread occurs first to inguinal nodes then pelvic nodes. US allows evalu- ation of the inguinal nodes and gives an opportunity to sample them with fine needle aspiration. If inguinal lymph nodes are malignant then further imaging is required to look for metastases with CT of the chest, abdomen, and pelvis (Figure 14.16).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.5.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most early stage penile cancers treatments include surgical removal and reconstruc- tion. Only in those unfit for surgery or who refuse surgery will suitability for radio- therapy be assessed. EBRT or brachytherapy are used in the treatment of infiltrating tumours T1–2 &lt;4 cm in diameter, with good results. Techniques typically use CT</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="189" alt="image" src="Image_218.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.16 <span class="s52">penile cancer. Ct showing enlarged, partly calcified left inguinal nodal mass (arrow) in a patient with carcinoma of the penis.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">planned volumes. Irradiation of regional lymph nodes is indicated postoperatively if there is extensive nodal involvement or in patients with recurrent or inoperable meta- static nodal disease.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.5.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Regular clinical follow-up of all patients is recommended. Local recurrence is best visualized with MRI. CT of the abdomen and pelvis are performed in the follow-up of patients with positive nodes at pelvic node dissection.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.5.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">US is often the first imaging modality to assess disease extent, and allows for fine needle aspiration of the inguinal nodes.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">MRI provides the greatest anatomical definition of local disease extent especially with reference to cavernosa and urogenital diaphragm infiltration.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">14.6 <span class="h4">Renal cell carcinoma</span></p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.6.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Renal cell carcinoma (RCC) is the eighth most common malignancy. Renal tumours are often detected incidentally on imaging. This has resulted in increased incidence of renal tumours, which are also now smaller at presentation. For patients with renal tumour without evidence of metastases, surgery with radical nephrectomy is the treat- ment of choice. Imaging plays an important part in deciding the surgical approach. In patients that are poor surgical candidates, various image-guided ablation techniques have been described, with radiofrequency and cryroablation showing good long-term disease specific and overall survival for T1 tumours.</p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.6.2 <span class="s29">Diagnosis and staging</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.6.2.1 <span class="s98">Characterizing renal mass lesions</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In suspected RCC, the first investigation performed is CT. Traditionally, it has been thought that a solid lesion on contrast-enhanced CT most likely represents a RCC, allowing for differentiation between tumours and pseudotumours. However, there is now increasing evidence that not all solid lesions are RCC, especially smaller lesions</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">&lt;3 cm. The differential diagnosis of a solid renal lesion includes angiomyolipomas, oncocytomas, lymphoma, or metastases. Cystic lesions are also common. They are described using the Bosniak classification on a scale of I–IV (Table 14.5<b>) </b>according to their complexity and likelihood of malignant potential.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MR is particularly useful for identifying haemorrhage, with increased signal on T1, decreased signal on T2, and no enhancement with contrast. Most RCCs are hyperintense on T2-weighted sequences, with variable T1 signal intensity. An updated</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 11pt;text-indent: 0pt;text-align: justify;">Table 14.5 <span class="s52">the Bosniak classification of renal cysts (proposed in 2019)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3622pt" cellspacing="0"><tr style="height:24pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-right: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bosniak class</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Features</p></td></tr><tr style="height:47pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">i</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;padding-right: 123pt;text-indent: 0pt;line-height: 111%;text-align: left;">pre-2019: simple cyst, no calcification or septa. post-2019</p><p class="s99" style="padding-left: 5pt;padding-right: 40pt;text-indent: 0pt;line-height: 111%;text-align: left;">Ct: homogenous water content (&lt;20 hu), no contrast enhancement. MR: homogenous signal enhancement similar to cerebrospinal fluid.</p></td></tr><tr style="height:78pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ii</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;padding-right: 87pt;text-indent: 0pt;line-height: 111%;text-align: justify;">pre-2019: benign cyst with fine calcification or thin septa. post-2019</p><p class="s99" style="padding-left: 10pt;padding-right: 12pt;text-indent: -5pt;line-height: 111%;text-align: justify;">Ct: six types, well defined (&lt;2 mm or too small to characterize) with varying hu levels, including small cystic with small number of septa.</p><p class="s99" style="padding-left: 10pt;padding-right: 23pt;text-indent: -5pt;line-height: 111%;text-align: justify;">MR: three types, well defined (&lt;2 mm or too small to characterize) including small cystic with small number of septa. Can have calcification or markedly intense t1 or t2 weighted without contrast.</p></td></tr><tr style="height:78pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiF</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 10pt;padding-right: 40pt;text-indent: -5pt;line-height: 111%;text-align: left;">pre-2019: multiple thin septa, coarse calcification, minimal wall thickening, &gt;3 mm.</p><p class="s99" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">post-2019</p><p class="s99" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Ct: smooth thickening or enhancing wall with one or more enhancing septa.</p><p class="s99" style="padding-top: 1pt;padding-left: 10pt;padding-right: 6pt;text-indent: -5pt;line-height: 111%;text-align: left;">MR: two types, smooth thickening or enhancing wall with one or more enhancing septa or cystic masses heterogeneously hyperintense on unenhanced fat-saturated t1 weighted.</p></td></tr><tr style="height:47pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iii</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;padding-right: 35pt;text-indent: 0pt;line-height: 111%;text-align: left;">pre-2019: thickened walls, contrast-enhanced, ~50% risk of malignancy. post-2019</p><p class="s99" style="padding-left: 5pt;padding-right: 40pt;text-indent: 0pt;line-height: 111%;text-align: left;">Ct: one or more enhancing thick (&gt;3 mm) or irregular wall or septa. MR: one or more enhancing thick (&gt;3 mm) or irregular wall or septa.</p></td></tr><tr style="height:47pt"><td style="width:34pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iV</p></td><td style="width:289pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 5pt;padding-right: 49pt;text-indent: 0pt;line-height: 111%;text-align: left;">pre-2019: enhancing soft tissue component, high risk of malignancy. post-2019</p><p class="s99" style="padding-left: 5pt;padding-right: 124pt;text-indent: 0pt;line-height: 111%;text-align: left;">Ct: one or more enhancing nodules (&gt;3 mm). MR: one or more enhancing nodules (&gt;3 mm).</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: justify;">source: data from silverman sG, et al. ‘Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment’. <span class="s83">Radiology</span>. Vol. 292, issue 2, pp.475–88. aug 2019 Rsna.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="300" height="210" alt="image" src="Image_219.gif"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.17 <span class="s52">Renal cell cancer. Ct shows large left renal cancer with extension into the renal vein (arrows) and enlarged left para-aortic nodes (arrowhead).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Bosniak classification has been described which incorporates information from CT and MRI (Table 14.5); clinical validation is awaited. If, despite this, the lesion remains indeterminate then image-guided biopsy or surgical excision may be undertaken.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.6.2.2 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Staging in renal cancer is performed with CT (Figure 14.17), with US and MRI re- served for problem-solving, for example venous extension of tumour (stage T3b–c disease), when US is highly accurate at assessing tumour thrombus within the IVC if the examination is technically adequate. Transoesophageal echocardiography may be helpful if tumour thrombus is suspected to extend into the right atrium. MRI is useful in delineating the extent of IVC thrombus and tumoral invasion of the IVC wall.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The presence of lymph node disease is a poor prognostic factor. On both CT and MRI, the diagnosis of lymph node involvement is based on size criteria, which has well-known limitations. In the assessment of metastatic disease a combination of CT and MRI of the body and brain and bone scintigraphy are performed as clinically indicated. Distant metastases occur most frequently in the lungs, and other sites in- clude bone, liver, contralateral kidney, adrenal, and brain. The role of FDG PET/CT in assessment for metastases in advanced renal cancer is limited as renal tumours have variable FDG uptake.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">14.6.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">RCC are relatively radio-insensitive; therefore radiotherapy does not form part of the primary treatment. However, advances in radiotherapy have resulted in the use of stereotactic ablative techniques (SBRT) using extreme hypofractionation in an attempt to ablate the tumour. SBRT planning will be CT based.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Radiotherapy is effective in the palliation of local symptoms due to metastatic dis- ease and has a role in the treatment of locally recurrent disease, usually based on CT imaging for localization of treatment volumes.</p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.6.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Imaging following radical nephrectomy should be based on a risk assessment using one of the published nomograms.<span class="s22">17 </span>Regular CT at six months and then annually to five years and two-yearly thereafter is recommended for high-risk patients; in contrast low-risk patients should have ultrasound at six months, followed by alternating CT and ultrasound for five years only.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.6.5 <span class="s29">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Renal mass lesions are best evaluated with CT; US, MRI, or biopsies are used where lesion remains indeterminate.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Staging is with CT.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Follow-up uses risk adapted US and CT.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7 <span class="h4">Urethral cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Urethral cancer is very rare, occurring more commonly in women and has a peak in- cidence in the seventh decade.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Urethral cancer is diagnosed clinically with cystoscopy and transurethral biopsy. Local staging evaluation is best made using MRI, again due to its excellent soft tissue con- trast resolution. T2-weighted sequences are used to define the primary tumour and local invasion. Contrast-enhanced T1-weighted sequences may be helpful and dem- onstrate a moderately enhancing tumour, local invasion, and fistulae. Urethral cancer principally spreads by local invasion and lymphatic spread is to the inguinal nodes if the distal urethra is involved and to the pelvic nodes if the proximal urethra is in- volved. Distant metastases are rare.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Local staging with MRI is used to assess tumour size, location, and local extension, and to plan radiotherapy treatment (Figure 14.18). Volume definition for radiotherapy is based on CT. For brachytherapy implantation, US-guided techniques are used.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Regular MRI of the pelvis is performed post-treatment to assess for local tumour re- currence, treatment-related complications, or to evaluate treatment.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">14.7.5 <span class="s29">Summary</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MRI is the imaging modality of choice for local staging and assists in treatment planning.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 82pt;text-indent: 0pt;text-align: left;"><span><img width="227" height="242" alt="image" src="Image_220.gif"/></span></p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 14.18 <span class="s52">urethral carcinoma. sagittal t2-weighted MR image of the penis showing locally invasive squamous cell cancer of the urethra (arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">1. <b>Ahmed HU</b>, <b>El-Shater Bosaily A</b>, <b>Brown LC, et al. </b>(2017). Diagnostic accuracy of multi- parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. <i>Lancet</i>, <b>389</b>(10071): 815–822.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">2. <b>Petralia G</b>, <b>Padhani AR</b>, <b>Pricolo P, et al. </b>(2018). Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. <i>Radiol Med, </i><b>124</b>(3): 218–233<i>.</i></p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">3. <b>Sonnad SS</b>, <b>Langlotz CP</b>, <b>Schwartz JS </b>(2001). Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change. <i>Academic Radiology</i>, <b>8</b>(2): 149–157.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">4. <b>Engelbrecht MR</b>, <b>Jager GJ</b>, <b>Laheij RJ</b>, <b>Verbeek AL</b>, <b>van Lier HJ</b>, <b>Barentsz JO </b>(2002). Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. <i>European Radioliology</i>, <b>12</b>(9): 2294–2302.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">5. <b>Husband JEaS SA </b>(1998). Prostate cancer. In: Husband JE RR, editor. <i>Imaging in Oncology</i>. Oxford: ISIS Medical Media. pp. 375–400.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">6. <b>Oyen RH</b>, <b>Van Poppel HP</b>, <b>Ameye FE</b>, <b>Van de Voorde WA</b>, <b>Baert AL</b>, <b>Baert LV (1994)</b>. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. <i>Radiology</i>, <b>190</b>(2): 315–322.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: left;">7. <b>Jager GJ</b>, <b>Barentsz JO</b>, <b>Oosterhof GO</b>, <b>Witjes JA</b>, <b>Ruijs SJ </b>(1996). Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI- weighted magnetization-prepared-rapid gradient-echo sequence. <i>American Journal of Roentgenology</i>, <b>167</b>(6): 1503–1507.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: justify;">8. <b>Thoeny HC</b>, <b>Barbieri S</b>, <b>Froehlich JM</b>, <b>Turkbey B</b>, <b>Choyke PL </b>(2017). Functional and targeted lymph node imaging in prostate cancer: current status and future challenges. <i>Radiology</i>, <b>285</b>(3): 728–743.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -10pt;text-align: justify;">9. <b>Woo S</b>, <b>Suh CH</b>, <b>Kim SY</b>, <b>Cho JY</b>, <b>Kim SH </b>(2018). The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated</p><p class="s74" style="padding-top: 4pt;padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">systematic review and diagnostic meta-analysis. <i>American Journal of Roentgenology</i>,</p><p class="s75" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">210<span class="s74">(3): W95–W109.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">10. <b>Herlemann A</b>, <b>Wenter V</b>, <b>Kretschmer A, et al. </b>(2016). (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. <i>European Urology</i>, <b>70</b>(4): 553–557.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">11. <b>O&#39;Donoghue EP</b>, <b>Constable AR</b>, <b>Sherwood T</b>, <b>Stevenson JJ</b>, <b>Chisholm GD </b>(1978). Bone scanning and plasma phosphatases in carcinoma of the prostate. <i>British Journal of Urology</i>, <b>50</b>(3): 172–177.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">12. <b>Rasch C</b>, <b>Barillot I</b>, <b>Remeijer P</b>, <b>Touw A</b>, <b>van Herk M</b>, <b>Lebesque JV </b>(1999). Definition of the prostate in CT and MRI: a multi-observer study. <i>International Journal of Radiation Oncology. Biology. Physics</i>, <b>43</b>(1): 57–66.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">13. <b>(NICE) NIfHaCE. Bladder cancer: diagnosis and management (Guidelines). </b><a href="https://www.nice.org.uk/guidance/ng2" class="a" target="_blank">Available from: </a>https://www.nice.org.uk/guidance/ng2.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">14. <b>Alfred Witjes J</b>, <b>Lebret T</b>, <b>Comperat EM, et al. </b>(2017). Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. <i>European Urology</i>, <b>71</b>(3): 462–475.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: justify;">15. <b>Schmoll HJ</b>, <b>Souchon R</b>, <b>Krege S, et al. </b>(2004). European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). <i>Annals of Oncology</i>, <b>15</b>(9): 1377–1399.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">16. <b>De Santis M</b>, <b>Becherer A</b>, <b>Bokemeyer C, et al. </b>(2014). 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. <i>Journal of Clinical Oncol</i>o<i>gy</i>, <b>22</b>(6): 1034–1039.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">17. <b>Ljungberg B</b>, <b>Bensalah K</b>, <b>Canfield S, et al. </b>(2015). EAU guidelines on renal cell carcinoma: 2014 update. <i>European Urology</i>, <b>67</b>(5): 913–924.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">18. <b>Sobin LH</b>, <b>Gospodarowicz MK</b>, <b>Wittekind CH </b>(2017). <i>UICC TNM Classification of Malignant Tumours </i>(eighth edn). Oxford: Wiley Blackwell.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part19.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part21.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
